SolasCure
PrivateLast Round
Accelerator
Jun 3, 2024
Total Funding Raised
$34.44M
Company Overview
SolasCure operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was an Accelerator round in June 2024.
SolasCure is a biotechnology company developing Aurase Wound Gel, a hydrogel-based therapeutic that uses a recombinant enzyme to debride chronic wounds and activate tissue repair.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SolasCure Comparables
Compare SolasCure with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ilya Pharma | 81% | |
| Mediwound Ltd | 78% | |
| Biotherapy Services | 76% |
For institutional investors. Book with your work email.
SolasCure Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Jun 3, 2024 | ||||
| Grant | Mar 20, 2024 | ||||
| Grant | Jun 1, 2023 | ||||
| Series B | Mar 27, 2023 | ||||
| Grant | Jan 11, 2023 | ||||
Series A | Oct 8, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
SolasCure Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| European Innovation Council Fund | Grant |
| Seneca Partners | Series A, Series B |
| Innovate UK | Accelerator, Grant |
| Texas Medical Center | Accelerator |
| Bionova Capital | Series A |
| Wealth Club | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 1, 2023
Received grant funding from the European Innovation Council.
- Mar 27, 2023
$13.3M round led by Seneca Partners.
For institutional investors. Book with your work email.
SolasCure Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SolasCure's valuation, stock price, and market status.
Is SolasCure a public or private company?
SolasCure is a private company.
What is the current stock price of SolasCure?
SolasCure is a private company, so its shares have no public market price. Caplight tracks SolasCure's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SolasCure worth (valuation)?
Valuation information for SolasCure is not publicly available.
Can I buy SolasCure stock?
SolasCure shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SolasCure's last funding round?
SolasCure's most recent funding round was Accelerator on June 3, 2024.
Who are the main investors in SolasCure?
Key investors in SolasCure include Seneca Partners.
Will SolasCure IPO soon?
No public IPO plans have been announced for SolasCure.
How can I track SolasCure secondary market activity?
Caplight tracks bids, offers, and trades in SolasCure's shares on secondary markets.